064 Short-term intravenous clindamycin accelerates the benefit of oral clindamycin-rifampicin treatment in hidradenitis suppurativa (HS)

Abstract

A 10-to-12-week course of combined clindamycin/rifampicin or tetracyclines are the first-line medical treatment for moderate-to-severe HS. A recent multicenter European study revealed significant efficacy of oral clindamycin/rifampicin and tetracyclines without differences between them, independently of baseline HS severity. Our study explored the efficacy of a treatment induction with a 5-day loading dose of i.v. clindamycin (3x600 mg/d) prior to the oral clindamycin/ rifampicin combination, in 95 consecutive, previous treatment-naive adult HS patients.